Abstract：
BACKGROUND: Sleep disturbance is common during methamphetamine (MA) use and withdrawal; however, the feasibility of combined subjective-objective measurement of sleep-wake has not been shown in this population. Actigraphy is a well-established, non-invasive measure of sleep-wake cycles with good concordance with polysomnography. This study aimed to investigate the feasibility and utility of using actigraphy and sleep diaries to investigate sleep during MA withdrawal.
METHODS: We conducted a feasibility and utility study of actigraphy and sleep diaries during a clinical trial of lisdexamfetamine for MA withdrawal. Participants were inpatients for 7 days, wore an actigraph (Philips Actiwatch 2) and completed a modified Consensus Sleep Diary each morning. Participants were interviewed between days 3-5.
RESULTS: Ten participants (mean age 37 years, 90% male) were enrolled. No participant removed the device prematurely. Participants interviewed (n = 8) reported that the actigraph was not difficult or distracting to wear or completion of daily sleep diary onerous. Actigraphic average daily sleep duration over 7 days was 568 min, sleep onset latency 22.4 min, wake after sleep onset (WASO) 75.2 min, and sleep efficiency 83.6%. Sleep diaries underreported daily sleep compared with actigraphy (sleep duration was 56 min (p = 0.008) and WASO 47 min (p < 0.001) less). Overall sleep quality was 4.4 on a nine-point Likert scale within the diary.
CONCLUSIONS: Continuous actigraphy is feasible to measure sleep-wake in people withdrawing from MA, with low participant burden. We found important differences in self-reported and actigraphic sleep, which need to be explored in more detail.
METHODS: We conducted a feasibility and utility study of actigraphy and sleep diaries during a clinical trial of lisdexamfetamine for MA withdrawal. Participants were inpatients for 7 days, wore an actigraph (Philips Actiwatch 2) and completed a modified Consensus Sleep Diary each morning. Participants were interviewed between days 3-5.
RESULTS: Ten participants (mean age 37 years, 90% male) were enrolled. No participant removed the device prematurely. Participants interviewed (n = 8) reported that the actigraph was not difficult or distracting to wear or completion of daily sleep diary onerous. Actigraphic average daily sleep duration over 7 days was 568 min, sleep onset latency 22.4 min, wake after sleep onset (WASO) 75.2 min, and sleep efficiency 83.6%. Sleep diaries underreported daily sleep compared with actigraphy (sleep duration was 56 min (p = 0.008) and WASO 47 min (p < 0.001) less). Overall sleep quality was 4.4 on a nine-point Likert scale within the diary.
CONCLUSIONS: Continuous actigraphy is feasible to measure sleep-wake in people withdrawing from MA, with low participant burden. We found important differences in self-reported and actigraphic sleep, which need to be explored in more detail.
摘要：
背景：在甲基苯丙胺（MA）的使用和戒断过程中，睡眠障碍很常见；但是，在这一人群中,主观-客观联合测量睡眠-觉醒的可行性尚未得到证实.活动是一个很成熟的，睡眠-觉醒周期的非侵入性测量与多导睡眠图具有良好的一致性。本研究旨在研究使用活动记录和睡眠日记来研究MA戒断期间睡眠的可行性和实用性。
方法：我们在一项用于MA戒断的lisdexamfetamine临床试验中进行了一项体动记录和睡眠日记的可行性和实用性研究。参与者住院7天，穿着活动记录仪（飞利浦Actiwatch2），每天早上完成修改后的共识睡眠日记。参与者在第3-5天之间接受采访。
结果：10名参与者(平均年龄37岁，90%男性）入组。没有参与者过早移除设备。接受采访的参与者（n=8）报告说，活动记录仪佩戴或完成每天繁重的睡眠日记并不困难或分散注意力。活动图7天的平均每日睡眠时间为568分钟，睡眠开始潜伏期22.4分钟，睡眠开始后醒来（WASO）75.2分钟，睡眠效率83.6%。与活动记录相比，睡眠日记少报了每日睡眠（睡眠持续时间为56分钟（p=0.008），WASO47分钟（p<0.001））。日记中的9点Likert量表的总体睡眠质量为4.4。
结论：连续活动描记术可用于测量从MA退出的人的睡眠-觉醒，低参与者负担。我们发现了自我报告和活动睡眠的重要差异，这需要更详细地探讨。
方法：我们在一项用于MA戒断的lisdexamfetamine临床试验中进行了一项体动记录和睡眠日记的可行性和实用性研究。参与者住院7天，穿着活动记录仪（飞利浦Actiwatch2），每天早上完成修改后的共识睡眠日记。参与者在第3-5天之间接受采访。
结果：10名参与者(平均年龄37岁，90%男性）入组。没有参与者过早移除设备。接受采访的参与者（n=8）报告说，活动记录仪佩戴或完成每天繁重的睡眠日记并不困难或分散注意力。活动图7天的平均每日睡眠时间为568分钟，睡眠开始潜伏期22.4分钟，睡眠开始后醒来（WASO）75.2分钟，睡眠效率83.6%。与活动记录相比，睡眠日记少报了每日睡眠（睡眠持续时间为56分钟（p=0.008），WASO47分钟（p<0.001））。日记中的9点Likert量表的总体睡眠质量为4.4。
结论：连续活动描记术可用于测量从MA退出的人的睡眠-觉醒，低参与者负担。我们发现了自我报告和活动睡眠的重要差异，这需要更详细地探讨。
